Add to Calendar:
*Attention In-Person Attendees
Proof of vaccination is required by the venue before you will be allowed to enter the building. You have two options:
Helpful Tip: Attain a digital COVID-19 vaccine record via state of California by clicking here, where you are able to take a screenshot of your QR code and keep for future proof.
Universal Masking/Face Coverings: All individuals will be required to wear a mask or face covering while indoors, regardless of vaccination status. The update is in line with the Centers for Disease Control and Prevention and the California Department of Public Health's recent recommendations on masking and face coverings.
You, you must complete a brief evaluation of our event in order to receive your CME certificate.
To begin, simply click on the link below, enter your personal information and begin the survey. At the end of the survey, you will be automatically emailed your CME certificate.
Please note that this evaluation must be completed and submitted online by December 5, 2022. This is the only way to confirm your attendance, which is required in order to receive CME credit.
COMPLETE CME CERTIFICATION EVALUATION HERE
The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement:
The University of California, Irvine School of Medicine designates this live activity for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit that is commensurate with the extent of their participation in the activity.
Parking is free
AcuFocus, Inc., is a privately held ophthalmic medical device company that delivers breakthrough small aperture intraocular products to address diverse unmet needs and help patients achieve their best personal vision. The IC-8 IOL is a first-of-its-kind presbyopia-correcting lens that delivers true extended depth of focus and enhanced adaptability through its distinctive, wavefront-filtering, small aperture design. The IC-8 IOL received CE mark in 2015 and is available in select markets across Europe and Asia.
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 20,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care.
Bausch + Lomb
By listening to feedback from customers, patients and consumers and using data-driven insights, we develop modernized vision care, consumer health care, surgical and pharmaceutical products to help millions of people worldwide see better to live better.
CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. Based in Seattle, the company is innovating the next generation of cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest products, delivery of the highest-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.
Dompé is an Italian biopharmaceutical company with a 130 year legacy of medical innovation. Based in Milan with US headquarters in the San Francisco Bay Area, Dompé is committed to medical and scientific advancements that address unmet medical needs in the areas of ophthalmology, transplants, oncology, and diabetes.
To learn more about Dompé, email USMedinfo@dompe.com
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Their mission is to transform the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.
Johnson Johnson Vision
At Johnson & Johnson Vision, we have a bold ambition: to change the trajectory of eye health. Through our operating companies, we've developed solutions for every stage of life-to help people see better, connect better and live better. We partner with eye care professionals to provide some of the world's leading products and technologies to address refractive error, cataracts, dry eye, and beyond. We are committed to using our reach and size for good and strive to put quality eye care within reach of everyone, everywhere.
Click logo to watch video
Learn more at www.jnjvisionpro.com/tecnissynergy
New World Medical
New World Medical was founded to benefit humanity. Our firm works to live up to this lofty goal by creating and manufacturing cutting-edge glaucoma surgical devices intended to alleviate the suffering of glaucoma patients globally. Dedicated surgical sales consultants provide support for New World Medical’s flagship products, which include the Ahmed® Glaucoma Valve, Ahmed ClearPath®, Kahook Dual Blade®, and KDB GLIDE® throughout the United States. Internationally, the company utilizes an exclusive distribution network to reach patients in need.
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform standards of care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare System is commercially available today as a wearable, office-based thermal eyelid technology that enables the controlled application of localized heat to the eyelids.
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials.
Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.
To learn more about Tarsus, please email firstname.lastname@example.org.
Visus Therapeutics is a team of industry leaders with vast eye care experience and an unmatched track record in the development and commercialization of innovative eye care pharmaceuticals. The breadth and depth of our collective knowledge and experience allows us to set our sights on the future of eye health, united by the common goal of advancing drug discovery to benefit the patients we serve and dedicated to achieving a lifetime of clear vision.
Click registration button to see further details for
Need to reach out to us for questions regarding the event? Or, are you interested in becoming a sponsor or exhibitor? Please contact Dana Collinson for more information.
Dana Collinson | 949-824-7243 | email@example.com